Monthly
US$200
Billed every month
Sign in to subscribeAs of 13 November 2026, for Diphenhydramine Hydrochloride Injection, 9 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 3 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: No longer listed under review: 1 application
Current coverage may be incomplete
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 3 of 3 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Injection. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| BENADRYL | MCNEIL CONSUMER HEALTHCARE | NDA 006146 · Product no. 001, 002 | INJECTABLE | INJECTION | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
| BENADRYL PRESERVATIVE FREE | MCNEIL CONSUMER HEALTHCARE | NDA 009486 · Product no. 001 | INJECTABLE | INJECTION | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| BENADRYL | MCNEIL CONSUMER HEALTHCARE | NDA 005845 · Product no. 001, 007 | CAPSULE | ORAL | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
| BENADRYL | MCNEIL CONSUMER HEALTHCARE | NDA 005845 · Product no. 004 | ELIXIR | ORAL | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
| BENYLIN | PARKE DAVIS DIV WARNER LAMBERT CO | NDA 006514 · Product no. 004 | SYRUP | ORAL | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Loaded records: 3 holders; 2 in the quality-and-efficacy consistency-evaluation category, and 1 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Shandong Zhi Tai Pharmaceuticals Technology Co., Ltd. romanized | Anhui Heng Xing Pharmaceutical Co., Ltd. romanized | 国药准字H20263032 | 2026/01/05 | 1ml: 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Sui Cheng Pharma Co., Ltd. romanized | Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20258253 | 2025/11/20 | 0.4ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Sui Cheng Pharma Co., Ltd. romanized | Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20258254 | 2025/11/20 | 1ml:50mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H20258139 | 2025/07/24 | 1ml:50mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 20 distinct approval numbers and 17 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Beijing Shi Yong Kang Pharma Co., Ltd. romanized | 国药准字H11020523 | 1ml:20mg | Category A | XR06AAB058B002010100137 | NHSA |
| Guangdong Bang Min Pharmaceutical Factory Co., Ltd. romanized | 国药准字H44021906 | 1ml:20mg | Category A | XR06AAB058B002010100267 | NHSA |
| Guangzhou Bai Yun Shan Ming Xing Pharmaceutical Co., Ltd. romanized | 国药准字H44022387 | 1ml:20mg | Category A | XR06AAB058B002010100375 | NHSA |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H31021087 | 1ml:20mg | Category A | XR06AAB058B002010100665 | NHSA |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H12020617 | 1ml:20mg | Category A | XR06AAB058B002010100874 | NHSA |
| Xi Nan Pharma Co., Ltd. romanized | 国药准字H50020144 | 1ml:20mg | Category A | XR06AAB058B002010100978 | NHSA |
| Ya Bang Pharmaceuticals Co., Ltd. romanized | 国药准字H32021435 | 1ml:20mg | Category A | XR06AAB058B002010101511 | NHSA |
| Hubei Ke Lun Pharma Co., Ltd. romanized | 国药准字H42021175 | 1ml:20mg | Category A | XR06AAB058B002010101871 | NHSA |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61021679 | 1ml:20mg | Category A | XR06AAB058B002010102503 | NHSA |
| Hebei Wan Cheng Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H13021443 | 1ml:20mg | Category A | XR06AAB058B002010102598 | NHSA |
| Topfond Pharmaceutical Co., Ltd. | 国药准字H41020354 | 1ml:20mg | Category A | XR06AAB058B002010103098 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41021792 | 1ml:20mg | Category A | XR06AAB058B002010103139 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H41021264 | 1ml:20mg | Category A | XR06AAB058B002010103204 | NHSA |
| Xin Xiang Shi Chang Le Pharmaceutical Co., Ltd. romanized | 国药准字H41020225 | 1ml:20mg | Category A | XR06AAB058B002010103216 | NHSA |
| Zhong Jia Bio Technology (Hubei Sheng) Co., Ltd. romanized | 国药准字H20053926 | 1ml:20mg | Category A | XR06AAB058B002010103377 | NHSA |
| Fujian Gu Tian Pharma Co., Ltd. romanized | 国药准字H35020106 | 1ml:20mg | Category A | XR06AAB058B002010104770 | NHSA |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H20258139 | 1ml:50mg | Category A | XR06AAB058B002010106917 | NHSA |
| Shandong Zhi Tai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263032 | 1ml:50mg | Category A | XR06AAB058B002010183094 | NHSA |
| Beijing Shi Yong Kang Pharma Co., Ltd. romanized | 国药准字H11020523 | 1ml:20mg | Category A | XR06AAB058B002010200137 | NHSA |
| Guangzhou Bai Yun Shan Ming Xing Pharmaceutical Co., Ltd. romanized | 国药准字H44022387 | 1ml:20mg | Category A | XR06AAB058B002010200375 | NHSA |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H31021087 | 1ml:20mg | Category A | XR06AAB058B002010200665 | NHSA |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H12020617 | 1ml:20mg | Category A | XR06AAB058B002010200874 | NHSA |
| Xi Nan Pharma Co., Ltd. romanized | 国药准字H50020144 | 1ml:20mg | Category A | XR06AAB058B002010200978 | NHSA |
| Ya Bang Pharmaceuticals Co., Ltd. romanized | 国药准字H32021435 | 1ml:20mg | Category A | XR06AAB058B002010201511 | NHSA |
| Hubei Ke Lun Pharma Co., Ltd. romanized | 国药准字H42021175 | 1ml:20mg | Category A | XR06AAB058B002010201871 | NHSA |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61021679 | 1ml:20mg | Category A | XR06AAB058B002010202503 | NHSA |
| Hebei Wan Cheng Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H13021443 | 1ml:20mg | Category A | XR06AAB058B002010202598 | NHSA |
| Topfond Pharmaceutical Co., Ltd. | 国药准字H41020354 | 1ml:20mg | Category A | XR06AAB058B002010203098 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H41021264 | 1ml:20mg | Category A | XR06AAB058B002010203204 | NHSA |
| Xin Xiang Shi Chang Le Pharmaceutical Co., Ltd. romanized | 国药准字H41020225 | 1ml:20mg | Category A | XR06AAB058B002010203216 | NHSA |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H20258139 | 1ml:50mg | Category A | XR06AAB058B002010206917 | NHSA |
| Shandong Zhi Tai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263032 | 1ml:50mg | Category A | XR06AAB058B002010283094 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20258253 | 0.4ml:20mg | Category A | XR06AAB058B002020103204 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41021792 | 1ml:20mg | Category A | XR06AAB058B002020203139 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20258253 | 0.4ml:20mg | Category A | XR06AAB058B002020203204 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20258254 | 1ml:50mg | Category A | XR06AAB058B002030103204 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20258254 | 1ml:50mg | Category A | XR06AAB058B002030203204 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 9 filings and 6 distinct first applicants.
Generic 5 · Supplement 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | CYHS2600837 | Generic | 2026/04/11 | Not stated by source | CDE |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | CYHS2600836 | Generic | 2026/04/11 | Not stated by source | CDE |
| Anhui Wei Er Man Pharmaceutical Co., Ltd. romanized | CYHS2601497 | Generic | 2026/06/25 | Not stated by source | CDE |
| Wuhan Bin Hu Shuang He Pharma Co., Ltd. romanized; Wuhan Fu Xing Bio Pharma Co., Ltd. romanized | CYHB2650133 | Supplement | 2026/06/10 | Not stated by source | CDE |
| Xin Xiang Shi Chang Le Pharmaceutical Co., Ltd. romanized | CYHB2650036 | Supplement | 2026/01/31 | Not stated by source | CDE |
| Xin Xiang Shi Chang Le Pharmaceutical Co., Ltd. romanized | CYHB2650035 | Supplement | 2026/01/31 | Not stated by source | CDE |
| Xin Xiang Shi Chang Le Pharmaceutical Co., Ltd. romanized | CYHB2650034 | Supplement | 2026/01/31 | Not stated by source | CDE |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized; E Mei Shan Tong Hui Pharmaceutical Co., Ltd. romanized | CYHS2503744 | Generic | 2025/10/21 | Not stated by source | CDE |
| Sichuan Tian Xing Hui Pharmaceuticals Technology Co., Ltd. romanized; Chengdu Bai Yu Pharmaceutical Co., Ltd. romanized | CYHS2503453 | Generic | 2025/09/18 | Not stated by source | CDE |
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | CYHS2600837 | Generic | 2026/04/11 | Not stated by source | CDE |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | CYHS2600836 | Generic | 2026/04/11 | Not stated by source | CDE |
| Anhui Wei Er Man Pharmaceutical Co., Ltd. romanized | CYHS2601497 | Generic | 2026/06/25 | Not stated by source | CDE |
Non-component matches: 18 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸苯海拉明 · No verified English name | Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. | Y20260000429 | I | Exact ingredient | 2026/05/29 | CDE |
| 盐酸苯海拉明 · No verified English name | Lian Yun Gang Gui Ke Pharma Co., Ltd. romanized | Y20250001034 | I | Exact ingredient | 2025/10/13 | CDE |
| 盐酸苯海拉明 · No verified English name | Jin Yao Pharma Co., Ltd. romanized | Y20240000952 | I | Exact ingredient | 2024/09/09 | CDE |
| 苯海拉明 · No verified English name | Jin Hong Pharma Co., Ltd. romanized | Y20240000477 | A | Salt-normalized ingredient | 2025/09/30 | CDE |
| 盐酸苯海拉明 · No verified English name | Yun Peng Pharmaceuticals Group Co., Ltd. romanized | Y20240000441 | A | Exact ingredient | 2026/01/22 | CDE |
| 盐酸苯海拉明 · No verified English name | Changchun Hai Yue Pharma Co., Ltd. romanized | Y20240000223 | A | Exact ingredient | 2026/09/29 | CDE |
| 盐酸苯海拉明 · No verified English name | Anhui Heng Xing Pharmaceutical Co., Ltd. romanized | Y20230001131 | A | Exact ingredient | 2026/11/10 | CDE |
| 枸橼酸苯海拉明 · No verified English name | Hefei En Rui Te Pharma Co., Ltd. romanized | Y20230001060 | I | Salt-normalized ingredient | 2023/11/24 | CDE |
| 盐酸苯海拉明 · No verified English name | Sichuan Sheng Yu Xin Pharma Co., Ltd. romanized | Y20230000805 | A | Exact ingredient | 2026/06/27 | CDE |
| 盐酸苯海拉明 · No verified English name | Bai Yun Shandong Tai Shang Qiu Pharma Co., Ltd. romanized | Y20230000405 | A | Exact ingredient | 2026/01/23 | CDE |
| 盐酸苯海拉明 · No verified English name | Supriya Lifescience Ltd. | Y20210001163 | A | Exact ingredient | 2025/09/28 | CDE |
| 盐酸苯海拉明 · No verified English name | Jilin Sheng Bo Da Wei Ye Pharmaceutical Co., Ltd. romanized | Y20230000277 | A | Exact ingredient | 2024/10/29 | CDE |
| 枸橼酸苯海拉明 · No verified English name | Zhi En Bio Technology Co., Ltd. romanized | Y20220001232 | A | Salt-normalized ingredient | 2026/02/26 | CDE |
| 盐酸苯海拉明 · No verified English name | Anhui Wei Er Man Pharmaceutical Co., Ltd. romanized | Y20210000548 | A | Exact ingredient | 2023/09/15 | CDE |
| 盐酸苯海拉明 · No verified English name | Wanbury Limited | Y20200000355 | A | Exact ingredient | 2026/06/13 | CDE |
| 苯海拉明 · No verified English name | Kongo Chemical Co., Ltd. | Y20200000683 | I | Salt-normalized ingredient | 2023/03/13 | CDE |
| 盐酸苯海拉明 · No verified English name | Shanghai Zhao Hui Pharma Co., Ltd. romanized | Y20190007179 | A | Exact ingredient | 2023/03/24 | CDE |
| 盐酸苯海拉明 · No verified English name | Shanghai Shang Yao Xin Ya Pharma Co., Ltd. romanized | Y20190007095 | A | Exact ingredient | 2023/03/24 | CDE |
| 盐酸苯海拉明 · No verified English name | Qi Dong Dong Yue Pharma Co., Ltd. romanized | Y20190006273 | A | Exact ingredient | 2026/01/08 | CDE |
| 盐酸苯海拉明 · No verified English name | Liao Yuan Shi Di Kang Pharma Co., Ltd. romanized | Y20190005518 | A | Exact ingredient | 2025/05/07 | CDE |
| 盐酸苯海拉明 · No verified English name | Hua Run Shuang He Pharma Co., Ltd. romanized | Y20190005444 | A | Exact ingredient | — | CDE |
| 盐酸苯海拉明 · No verified English name | Beijing Tai Yang Pharma Co., Ltd. romanized | Y20190004759 | A | Exact ingredient | 2025/04/23 | CDE |
| 盐酸苯海拉明 · No verified English name | Liao Yuan Shi Bai Kang Pharma Co., Ltd. romanized | Y20190002144 | A | Exact ingredient | 2025/03/22 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
CYHS2501704
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2025/05/10
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy